Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice

Journal of Immunology

Volumn 171, Issue 6, 2003, Pages 2922-2929

  Li, Jian ^a   Li, Weiping ^a   Liang, Shaohong ^a   Cai, Dewei ^a   Kieny, Marie Paule ^b   Jacob, Lutz ^a   Linnenbach, Alban ^a   Abramczuk, Jan W ^a   Bender, Hans ^a   Sproesser, Katrin ^a   Swoboda, Rolf ^a   Somasundaram, Rajasekharan ^a   Guerry, DuPont ^a   Herlyn, Dorothee ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSERM   (France)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; RECOMBINANT CD63 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER; HEMADSORPTION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0042834330     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.6.2922     Document Type: Article

References (55)

1. Forrester, K., C. Almoguera, K. Han, W. E. Grizzle, and M. Perucho. 1987. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327:298.
2. Lane, D. E. 1992. Cancer: p53, guardian of the genome. Nature 358:15.
3. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704.
4. Hellstrom, I., and K. E. Hellstrom. 1998. T cell immunity to tumor antigens. Crit. Rev. Immunol. 18:1.
5. Jaffee, E. M., and D. M. Pardoll. 1996. Murine tumor antigens: is it worth the search? Curr. Opin. Immunol. 8:622.
6. Kawakami, Y., and S. A. Rosenberg. 1997. Human tumor antigens recognized by T-cells. Immunol. Res. 16:313.
7. Van den Eynde, B. J., and T. Boon. 1997. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res. 27:81.
8. Van den Eynde, B. J., and P. Van der Brugen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9:684.
9. Basak, S., S. Eck, R. Gutzmer, A. J. Smith, B. Birebent, E. Purev, L. Staib, R. Somasundaram, J. Zaloudik, W. Li, et al. 2000. Colorectal cancer vaccines: anti-idiotypic antibody, recombinant protein, and viral vector. Ann. NY Acad. Sci. 910:237.
10. Reilly, R. T., M. B. C. Gottlieb, A. M. Ercolini, J.-P. H. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60:3569.
11. Herlyn, D., M. Wettendorff, E. Schmoll, D. Iliopoulos, I. Schedel, U. Dreikhausen, R. Raab, A. H. Ross, H. Jaksche, M. Scriba, and H. Koprowski. 1987. Anti-idiotype immunization in cancer patients: modulation of the immune response. Proc. Natl. Acad. Sci. USA 84:8055.
12. Nakamura, H., Y. Hinoda, N. Nakagawa, Y. Makiguchi, F. Itoh, T. Endo, and K. Imai. 1998. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. 33:354.
13. Stockert, E., E. Jäger, Y.-T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187:1349.
14. Mosolits, S., U. Harmenberg, U. Ruden, L. Ohman, B. Nilsson, B. Wahren, J. Fagerberg, and H. Mellstedt. 1999. Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother. 47:315.
15. Clarke, P., J. Mann, J. F. Simpson, K. Rickard-Dickson, and F. J. Primus. 1998. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58:1469.
16. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J. W. Greiner. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59:676.
17. Mizobata, S., K. Tompkins, J. F. Simpson, Y. Shyr, and F. J. Primus. 2000. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol. Immunother. 49:285.
18. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161:5500.
19. Acres, B., V. Apostolopoulos, J.-M. Balloul, D. Wreschner, P.-X. Xing, D. Ali-Hadji, N. Bizouarne, M. P. Kieny, and I. F. C. McKenzie. 2000. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother. 48:588.
20. Carr-Brendel, V., D. Markovic, K. Ferrer, M. Smith, J. Taylor-Papadimitriou, and E. P. Cohen. 2000. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res. 60:2435.
21. Koido, S., M. Kashiwaba, D. Chen, S. Gendler, D. Kufe, and J. Gong. 2000. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165:5713.
22. Wilkinson, R. W., E. L. Ross, A. E. Lee-MacAry, R. Laylor, J. Burchell, J. Taylor-Papadimitriou, and D. Snary. 2000. A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1. Br. J. Cancer 83:1202.
23. Soares, M. M., V. Mehta, and O. J. Finn. 2001. Three different vaccines based on the 140-amino acid Muc1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus Muc1 transgenic mice with different potential for tumor rejection. J. Immunol. 166:6555.
24. Wei, C., R. A. Willis, B. R. Tilton, R. J. Looney, E. M. Lord, R. Barth, and J. G. Frelinger. 1997. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc. Natl. Acad. Sci. USA 94:6369.
25. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J. Immunol. 161:5133.
26. Cefai, D., B. W. Morrison, A. Sckell, L. Favre, M. Balli, M. Leunig, and C. D. Gimmi. 1999. Targeting Her-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int. J. Cancer 83:393.
27. Grosenbach, D. W., J. C. Barrientos, J. Schlom, and J. W. Hodge. 2001. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61:4497.
28. Greiner, J. W., H. Zeytin, M. R. Anver, and J. Schlom. 2002. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62:6944.
29. Atkinson, B., C. S. Ernst, B. F. D. Ghrist, M. Herlyn, M. Blaszczyk, A. H. Ross, D. Herlyn, Z. Steplewski, and H. Koprowski. 1984. Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res. 44:2577.
30. Atkinson, B., C. S. Ernst, B. F. D. Ghrist, A. H. Ross, and W. H. Clark. 1985. Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma 4:243.
31. Vennegoor, C., J. Calafat, P. Hageman, F. van Buttenen, H. Janssen, A. Kolk. and P. Rümke. 1985. Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3. Int. J. Cancer 35:287.
32. Sikora, L. K. J., A. Pinto, D. J. Demetric, W. T. Dixon, S. J. Urbanski, W. Temple, and L. M. Jerry. 1987. Characterization of a novel neuroglandular antigen (NGA) expressed on abnormal human melanocytes. Int. J. Cancer 39:138.
33. Metzelaar, M. J., P. L. Wungaard, P. J. Peters, J. J. Sixma, H. K. Nieuwenhuis, and H. C. Clevers. 1991. CD63 antigen: a novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J. Biol. Chem. 266:3239.
34. Ernst, C. S., J.-W. Shen, S. Litwin, M. Herlyn, H. Koprowski, and H. F. Sears. 1986. Multiparameter evaluation of the expression in situ of normal and tumor-associated antigens in human colorectal carcinoma. J. Natl. Cancer Inst. 77:387.
35. Reisfeld, R. A. 1993. Report of the international consensus conference on human melanoma antigens. Melanoma Res. 3:209.
36. Smith, M., R. Bleijs, K. Radford, and P. Hersey. 1997. Immunogenicity of CD63 in a patient with melanoma. Melanoma Res. 7:S163.
37. Hotta, H., A. H. Ross, K. Huebner, M. Isobe, S. Wendeborn, M. V. Chao, R. P. Ricciardi, Y. Tsujimoto, C. M. Croce, and H. Koprowski. 1988. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res. 48:2955.
38. Herlyn, M., W. H. Clark, Jr., M. J. Mastrangelo, D. P. Guerry IV, D. E. Elder, D. LaRossa, R. Hamilton, E. Bondi, R. Tuthill, Z. Steplewski, and H. Koprowski. 1980. Specific immunoreactivity of monoclonal anti-melanoma antibodies. Cancer Res. 40:3602.
39. Demetrick, D. J., D. Herlyn, M. Tretiak, D. Creasey, H. Clevers, L. A. Donoso, C. J. Vennegoor, W. T. Dixon, and L. M. Jerry. 1992. The ME491 melanoma-associated glycoprotein family: antigenic identification of the ME491. NKI/C-3, NGA and CD63 proteins. J. Natl. Cancer Inst. 84:422.
40. Herlyn, D., J. Powe, A. H. Ross, M. Herlyn, and H. Koprowski. 1985. Inhibition of human tumor growth by IgG2a monoclonal antibodies correlates with antibody density on tumor cells. J. Immunol. 134:1300.
41. Scatchard, G. 1949. The attraction of proteins for small molecules and ions. Ann. NY Acad. Sci. 51:660.
42. Li, W., K. Berencsi, S. Basak, R. Somasundaram, R. P. Ricciardi, E. Gonczol, J. Zaloudik, A. Linnenbach, H. Maruyama, P. Miniou, and D. Herlyn. 1997. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by recombinant adenovirus inhibits growth of established CRC cells in mice. J. Immunol. 159:763.
43. Kieny, M. P., R. Lathe, and J. P. Lecocq. 1983. New versatile cloning and sequencing vectors based on bacteriophage M13. Gene 26:91.
44. Kieny, M. P., G. Rautmann, D. Schmitt, K. Dott, S. Wain-Hobson, M. Girard, S. Chamaret, A. Laurent, L. Montagnier, and J. P. Lecocq. 1986. AIDS virus env protein expressed from a recombinant vaccinia virus. Biotechnology 4:790.
45. Herlyn, D., R. Somasundaram, J. Zaloudik, W. Li, L. Jacob, D. Harris, M.-P. Kieny, R. Ricciardi, E. Gonczol, H. F. Sears, and M. J. Mastrangelo. 1995. Cloned antigens and anti-idiotypes. Hybridoma 14:159.
46. Zaloudik, J., W. Li, L. Jacob, M. P. Kieny, R. Somasundaram, B. Acres, H. Song, T. Zhang, J. Li, and D. Herlyn. 2002. Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther. 9:382.
47. Bronte, V., K. Tsung, J. B. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N. P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282.
48. Apostolopoulos, V., G. Pietersz, B. Loveland, M. Sandrin, and I. McKenzie. 1995. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA 92:10128.
49. + T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166:2863.
50. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate native or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
51. Vierboom, M. P., H. W. Nijman, R. Offringa, E. I. van-der-Voort, T. van-Hall, L. van-den-Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. Melief. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:695.
52. Morgan, D., H. Kreuwel, S. Fleck, H. Levitsky, D. Pardoll, and L. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
53. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in vitro in antigen transgenic mice. Cell 65:305.
54. Lees, C. J., V. Apostolopoulos, B. A. Acres, C. S. Ong, V. Popovski, and I. F. C. McKenzie. 2000. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mammalian-MUC1. Cancer Immunol. Immunother. 48:644.
55. Tsang, K. Y., S. Zaremba, C. A. Nieroda, M. Z. Zhu, J. M. Hamilton, and J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:949.